Web Results

Gemtuzumab ozogamicin - Wikipedia

en.wikipedia.org/wiki/Gemtuzumab_ozogamicin

Gemtuzumab ozogamicin is a drug-linked monoclonal antibody (an antibody- drug conjugate) that was used to treat acute myelogenous leukemia from 2000 to  ...

Gemtuzumab Ozogamicin - Drug Information - Chemocare

chemocare.com/chemotherapy/drug-info/gemtuzumab-ozogamicin.aspx

Mylotarg is the trade name for gemtuzumab ozogamicin. In some cases, health care professionals may use the trade name mylotarg when referring to the ...

Gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth) ADC Review

adcreview.com/gemtuzumab-ozogamicin-mylotarg/

Jul 19, 2015 ... Gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) is a recombinant, humanized anti-CD33 monoclonal antibody (IgG4 κ ...

Gemtuzumab Ozogamicin: Time to Resurrect?: Journal of Clinical ...

ascopubs.org/doi/full/10.1200/jco.2012.43.0132

On May 17, 2000, the US Food and Drug Administration (FDA) granted accelerated approval for the use of gemtuzumab ozogamicin (GO) in older patients (age ...

Safety Alerts for Human Medical Products > Mylotarg (gemtuzumab ...

www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm216458.htm

Mylotarg (gemtuzumab ozogamicin): Market Withdrawal. Audience: Oncology, Hematology. [Posted 06/21/2010]. ISSUE: FDA notified healthcare professionals  ...

Gemtuzumab ozogamicin in acute myeloid leukemia: a ... - NCBI

www.ncbi.nlm.nih.gov/pubmed/23591788

Blood. 2013 Jun 13;121(24):4838-41. doi: 10.1182/blood-2013-03-490482. Epub 2013 Apr 16. Gemtuzumab ozogamicin in acute myeloid leukemia: a ...

Mylotarg - FDA prescribing information, side effects and uses

www.drugs.com/pro/mylotarg.html

Mylotarg® (gemtuzumab ozogamicin for Injection) is a chemotherapy agent composed of a recombinant humanized IgG4, kappa antibody conjugated with a  ...

MYLOTARG, INN: gemtuzumab ozogamicin

www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000705/WC500070677.pdf

EMEA/CHMP/5130/2008. REFUSAL ASSESSMENT REPORT. FOR. MYLOTARG . International Nonproprietary Name: gemtuzumab ozogamicin. Procedure No.

Gemtuzumab ozogamicin: Indications, Side Effects, Warnings ...

www.drugs.com/cdi/gemtuzumab-ozogamicin.html

Easy to read patient leaflet for gemtuzumab ozogamicin. Includes indications, proper use, special instructions, precautions, and possible side effects.

Gemtuzumab ozogamicin Pathway, Pharmacokinetics ... - PharmGKB

www.pharmgkb.org/pathway/PA166115250

Background: Gemtuzumab ozogamicin (GO) is an immunoconjugate between an anti-CD33 antibody and a cytotoxic calicheamicin derivative (N-acetyl g1 ...

More Info

Gemtuzumab Ozogamicin Voluntarily Withdrawn from U.S. Markets ...

www.cancer.gov

Jun 24, 2010 ... Pfizer, Inc., in agreement with the FDA, announced their discontinuing commercial marketing of gemtuzumab ozogamicin (Mylotarg) as of ...

Gemtuzumab ozogamicin in acute myeloid leukemia - Blood Journal

www.bloodjournal.org

Gemtuzumab ozogamicin (GO) consists of a humanized anti-CD33 monoclonal antibody conjugated with calicheamicin, a potent antitumor anthracycline ...

Gemtuzumab (Mylotarg®) - Cancer Information - Macmillan Cancer ...

www.macmillan.org.uk

Information about the monoclonal antibody gemtuzumab (Mylotarg®), which is mainly used as part of research trials to treat some types of acute myeloid ...